Boehringer Ingelheim

87 results found.

Neoplasms Clinical Trial using BI 836845

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Dose Escalation Trial of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours During Escalation and Weekly in Selected Tumour Types During Expansion, With Repeated Administrations in Patients Showing Clinical Benefit..
BI 836845

Pulmonary Disease, Chronic Obstructive Clinical Trial using placebo; ipratropium bromide

Boehringer Ingelheim - Recruiting 50 years to 75 years.
- Peri-operative Intervention With Nebulized Ipratropium Bromide in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial..
placebo; ipratropium bromide

Pulmonary Disease, Chronic Obstructive Clinical Trial using tiotropium; placebo; olodaterol

Boehringer Ingelheim - Recruiting 40 years or older.
- A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
tiotropium; placebo; olodaterol

Idiopathic Pulmonary Fibrosis Clinical Trial using Matching Placebo; Nintedanib

Boehringer Ingelheim - Recruiting 40 years or older.
- A Double Blind Randomized Placebo Controlled Trial Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Twelve Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months.
Matching Placebo; Nintedanib

Pulmonary Disease, Chronic Obstructive Clinical Trial using olodaterol; tiotropium; placebo

Boehringer Ingelheim - Recruiting 40 years or older.
- A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
olodaterol; tiotropium; placebo

Intestinal Diseases Clinical Trial using 654-II (anisodamine); Buscopanr (hyoscine butylbromide)

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopanr Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain.
654-II (anisodamine); Buscopanr (hyoscine butylbromide)

Myelodysplastic Syndromes, or Leukemia, Myelomonocytic, Chronic Clinical Trial using Azacitidine; Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Ineligible for High-intensity Therapy.
Azacitidine; Volasertib

Catheter Obstruction, or Vascular Access Devices Clinical Trial using Actilyse; Saline solution

Boehringer Ingelheim - Recruiting 18 years to 80 years.
- A Multicenter, Open-label, Randomised, Clinical Trial to Compare the Efficacy and Safety of Actilyse 2 mg/ 2 ml Versus Saline Solution in Restoring Function of an Occluded Central Venous Access Device.
Actilyse; Saline solution

Leukemia, Myeloid, Acute Clinical Trial using Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia.
Volasertib

Diabetes Mellitus, Type 2 Clinical Trial using Linagliptin; Empagliflozin + Linagliptin; Empaglifozin placebo + Linagliptin placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy..
Linagliptin; Empagliflozin + Linagliptin; Empaglifozin placebo + Linagliptin placebo

Healthy Clinical Trial using Faldaprevir; Cyclosporine; Tacrolimus

Boehringer Ingelheim - Recruiting 18 years to 50 years.
- Investigation of Potential Drug-drug Interactions Between Faldaprevir and Immunosuppressants (Cyclosporine and Tacrolimus) in Healthy Male and Female Subjects (Open-label, Fixed-sequence Trial).
Faldaprevir; Cyclosporine; Tacrolimus

Pulmonary Disease, Chronic Obstructive Clinical Trial using olodaterol; tiotropium; Placebo

Boehringer Ingelheim - Recruiting 40 years or older.
- A Randomised, Placebo-controlled, Double-blind, Single Dose, Cross-over Study to Evaluate the Efficacy and Safety of Orally Inhaled Tiotropium + Olodaterol as Both a Fixed Dose Combination and a Free Combination (Both Delivered by the Respimatr Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD).
olodaterol; tiotropium; Placebo

Healthy Clinical Trial using Placebo to BI 1026706; Pregabalin; BI 1026706; Celecoxib

Boehringer Ingelheim - Recruiting 18 years to 55 years.
- Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB (Ultraviolet)-Irradiated Skin in Healthy Male Volunteers (a Single-blinded, Randomised, Placebo-controlled, Single-dose, Five-way Crossover Study).
Placebo to BI 1026706; Pregabalin; BI 1026706; Celecoxib

Neoplasms Clinical Trial using BIBW 2992; BIBF 1120

Boehringer Ingelheim - Recruiting 18 years or older.
- Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours..
BIBW 2992; BIBF 1120

Leukemia, Myeloid, Acute Clinical Trial using placebo; volasertib; low dose cytarabine

Boehringer Ingelheim - Recruiting N/A or older.
- A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy.
placebo; volasertib; low dose cytarabine

Arthritis, Rheumatoid, or Healthy Clinical Trial using BI 655064 medium dose; BI 655064 high dose; Placebo; BI 655064 low dose

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy.
BI 655064 medium dose; BI 655064 high dose; Placebo; BI 655064 low dose

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
afatinib

Diabetes Mellitus, Type 2 Clinical Trial using Trajenta duo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta Duo® (Linagliptin/Metformin HCl, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, b.i.d) in Korean Patients With Type 2 Diabetes Mellitus.
Trajenta duo

Neoplasms Clinical Trial using BI 860585; exemestane; paclitaxel

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours.
BI 860585; exemestane; paclitaxel

Rhinitis Clinical Trial

Boehringer Ingelheim - Recruiting 6 years or older.
- Treatment With Rhinospray Plus of Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary.

Leukemia, or Neoplasms Clinical Trial using volasertib

Boehringer Ingelheim - Recruiting 2 years to 17 years.
- Open, Non-controlled, Dose Escalating Phase I Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Tolerability and Toxicity of Volasertib in Paediatric Patients From 2 Years to Less Than 18 Years of Age With Acute Leukaemia or Advanced Solid Tumour, for Whom no Effective Treatment is Known.
volasertib

Hypertension Clinical Trial using Telmisartan + amlodipine; hydrochlorothiazide; Placebo

Boehringer Ingelheim - Recruiting 20 years or older.
- An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg.
Telmisartan + amlodipine; hydrochlorothiazide; Placebo

Crohn Disease Clinical Trial using BI 655066 (high dose); BI 655066 (low dose); BI 655066 one dose; placebo dose

Boehringer Ingelheim - Recruiting 18 years to 75 years.
- A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066, an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are na‹ve to, or Were Previously Treated With Anti-TNF Therapy..
BI 655066 (high dose); BI 655066 (low dose); BI 655066 one dose; placebo dose

Healthy Clinical Trial using BI 1181181; BI 1181181, R; BI 1181181, T2; Placebo to BI 1181181; BI 1181181, T1

Boehringer Ingelheim - Recruiting 18 years to 50 years.
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability and the Effect of Food on the Pharmacokinetics of BI 1181181(Open-label, Randomised, Three-way Cross-over Design).
BI 1181181; BI 1181181, R; BI 1181181, T2; Placebo to BI 1181181; BI 1181181, T1

Atrial Fibrillation Clinical Trial using pantoprazole; Pradaxa (dabigatran etexilate); Pradaxa, within 30 minutes after a meal

Boehringer Ingelheim - Recruiting 18 years or older.
- A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa® With Food (Within 30 Minutes After a Meal) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment With Pradaxa® 150 mg b.i.d., 110 mg b.i.d. or 75 mg b.i.d. for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation (NVAF).
pantoprazole; Pradaxa (dabigatran etexilate); Pradaxa, within 30 minutes after a meal

Diabetes Mellitus, Type 2 Clinical Trial using Trajenta tablet

Boehringer Ingelheim - Recruiting 19 years or older.
- A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study).
Trajenta tablet

Hepatitis C, Chronic Clinical Trial using Faldaprevir; BI 207127; BI 207127 high dose; Ribavirin placebo; BI 207127 high dose placebo; Ribavirin; Faldaprevir placebo; BI 207127 low dose; BI 207127 low dose placebo

Boehringer Ingelheim - Recruiting 18 years to 75 years.
- A Phase III Randomised, Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection.
Faldaprevir; BI 207127; BI 207127 high dose; Ribavirin placebo; BI 207127 high dose placebo; Ribavirin; Faldaprevir placebo; BI 207127 low dose; BI 207127 low dose placebo

Diabetes Mellitus, Type 2, or Healthy Clinical Trial using Empagliflozin; BI 10773

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- An Open-label Mechanistic Study to Examine the Effect of Oral Empagliflozin (25 mg q.d.) on Kinetics of Renal Glucose Reabsorption in Patients With Type 2 Diabetes Mellitus and Healthy Controls.
Empagliflozin; BI 10773

Venous Thromboembolism Clinical Trial using dabigatran etexilate; standard of care

Boehringer Ingelheim - Recruiting N/A to 17 years.
- Open-label, Randomized, Parallel-group, Active-controlled, Multi-centre Non-inferiority Study of Dabigatran Etexilate Versus Standard of Care for Venous Thromboembolism Treatment in Children From Birth to Less Than 18 Years of Age.
dabigatran etexilate; standard of care

Stroke, or Atrial Fibrillation Clinical Trial

Boehringer Ingelheim - Recruiting 18 years or older.
- GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland).

Diabetes Mellitus, Type 1 Clinical Trial using Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Boehringer Ingelheim - Recruiting 18 years to 65 years.
- A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2).
Empagliflozin medium placebo; Empagliflozin low placebo; Empagliflozin high placebo; Empagliflozin medium; Empagliflozin low; Empagliflozin high

Neoplasms Clinical Trial using Cetuximab( erbituxr); Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase Ib Dose Escalation Study of Afatinib in Combination With Cetuximab in Patients With Advanced Solid Tumours.
Cetuximab( erbituxr); Afatinib

Hypertension Clinical Trial using Twynsta tablet

Boehringer Ingelheim - Recruiting 19 years or older.
- A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy.
Twynsta tablet

Diabetes Mellitus, Type 2 Clinical Trial using Placebo; Linagliptin 5mg

Boehringer Ingelheim - Recruiting 18 years to 80 years.
- A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin).
Placebo; Linagliptin 5mg

Head and Neck Neoplasms Clinical Trial using methotrexate; afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy.
methotrexate; afatinib

Pulmonary Disease, Chronic Obstructive Clinical Trial using Placebo to BI 113608 high dose b.i.d.; Placebo to BI 113608 low dose b.i.d.; BI 113608 high dose b.i.d.; Placebo to BI 113608 medium dose b.i.d.; BI 113608 low dose b.i.d.; BI 113608 medium dose b.i.d.

Boehringer Ingelheim - Recruiting 40 years to 80 years.
- Randomized, Placebo-controlled, Double-blind Within Dose Groups, Multiple Rising-dose Study to Evaluate Safety, Tolerability, and PK of Oral BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With COPD Associated With Chronic Bronchitis.
Placebo to BI 113608 high dose b.i.d.; Placebo to BI 113608 low dose b.i.d.; BI 113608 high dose b.i.d.; Placebo to BI 113608 medium dose b.i.d.; BI 113608 low dose b.i.d.; BI 113608 medium dose b.i.d.

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies.
BI 853520

Head and Neck Neoplasms Clinical Trial using Placebo; Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma.
Placebo; Afatinib

Asthma Clinical Trial using Tiotropium low dose QD; Tiotropium high dose QD; Placebo

Boehringer Ingelheim - Recruiting 6 years to 11 years.
- A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimatr Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma.
Tiotropium low dose QD; Tiotropium high dose QD; Placebo

Diabetes Mellitus, Type 2 Clinical Trial using OAD; Trazenta

Boehringer Ingelheim - Recruiting N/A or older.
- Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus.
OAD; Trazenta

Diabetes Mellitus, Type 2 Clinical Trial using BI 10773; BI 10773 Placebo; BI 10773 / BI 1356; BI 10773 / BI 1356 Placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy.
BI 10773; BI 10773 Placebo; BI 10773 / BI 1356; BI 10773 / BI 1356 Placebo

Healthy Clinical Trial using BI 113608; Placebo

Boehringer Ingelheim - Recruiting 20 years to 45 years.
- Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 113608 in Healthy Male Asian and Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups).
BI 113608; Placebo

Pulmonary Disease, Chronic Obstructive Clinical Trial using Combivent Respimat via ventilator adapter

Boehringer Ingelheim - Recruiting 40 years or older.
- Open Label, Non-randomised, 1-day Trial to Characterize the Performance of an Adapter Device Designed to Permit Use of the Respimatr Inhaler Device With Patients Requiring Mechanical Ventilation..
Combivent Respimat via ventilator adapter

Atrial Fibrillation Clinical Trial using Pradaxa (Dabigatran etexilate mesilate)

Boehringer Ingelheim - Recruiting 19 years or older.
- A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Pradaxa (Dabigatran Etexilate Mesilate, 110 mg or 150 mg b.i.d.) in Korean Patients With Non-valvular Atrial Fibrillation(SPARK: Safety Study of Pradaxa in AF Patients by Regulatory Requirement of Korea).
Pradaxa (Dabigatran etexilate mesilate)

Mesothelioma Clinical Trial using Nintedanib; Pemetrexed; Cisplatin; Placebo

Boehringer Ingelheim - Recruiting 18 years or older.
- Double Blind, Randomised, Multicentre, Phase II Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma.
Nintedanib; Pemetrexed; Cisplatin; Placebo

Pulmonary Disease, Chronic Obstructive Clinical Trial using Tiotropium Bromide 2.5 æg; Indacterol 300 æg; Tiotropium Bromide 18 æg; Indacterol 150 æg

Boehringer Ingelheim - Recruiting 40 years or older.
- Post-Marketing Observational Study of the Impact of Adherence to Treatment With Once-Daily Administered Long-Acting Bronchodilators (LABAs / LAMAs) on Patients Health Related Quality of Life in COPD Patients.
Tiotropium Bromide 2.5 æg; Indacterol 300 æg; Tiotropium Bromide 18 æg; Indacterol 150 æg

Hemorrhage Clinical Trial using BI 655075; Placebo

Boehringer Ingelheim - Recruiting 45 years to 80 years.
- Randomised, Double-blind, Placebo-controlled, Two-way Cross-over Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655075 and to Establish the Efficacy of BI 655075 in Reversal of Dabigatran Anticoagulant Activity in Volunteers.
BI 655075; Placebo

Healthy Clinical Trial using BI 1034020; Placebo to BI 1034020

Boehringer Ingelheim - Recruiting 18 years to 40 years.
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study).
BI 1034020; Placebo to BI 1034020

Healthy Clinical Trial using BI 655075; Placebo to dose; Placebo to BI 655075; dabigatran

Boehringer Ingelheim - Recruiting 20 years to 45 years.
- Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2)..
BI 655075; Placebo to dose; Placebo to BI 655075; dabigatran

Spondylitis, Ankylosing Clinical Trial using Placebo; BI 655066

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis..
Placebo; BI 655066

Arthritis, Rheumatoid Clinical Trial using BI 695500; rituximab

Boehringer Ingelheim - Recruiting 18 years to 80 years.
- Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial..
BI 695500; rituximab

Pulmonary Disease, Chronic Obstructive Clinical Trial using Group1:Spirivar Respimatr; Group2:Hirobrizr/Oslifr/Onbrezr Breezhalerr

Boehringer Ingelheim - Recruiting 18 years or older.
- Cross-sectional Study to Assess the Handling , Patient Satisfaction, and Preference for Inhalation Devices in Patients With Chronic Obstructive Pulmonary Disease (COPD)..
Group1:Spirivar Respimatr; Group2:Hirobrizr/Oslifr/Onbrezr Breezhalerr

Diabetes Mellitus, Type 2 Clinical Trial using Placebo; Linagliptin

Boehringer Ingelheim - Recruiting 18 years or older.
- CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk.
Placebo; Linagliptin

Neoplasms Clinical Trial using Carboplatin; BIBW 2992; Paclitaxel; BIBW2992; Bevacizumab

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Open Label Trial of Continuous Dosing With BIBW 2992 Combined With Paclitaxel and BIBW 2992 Combined With Paclitaxel and Bevacizumab, BIBW 2992 Combined With Carboplatin and BIBW 2992 Combined With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumours.
Carboplatin; BIBW 2992; Paclitaxel; BIBW2992; Bevacizumab

Asthma Clinical Trial using tiotropium-bromide; placebo

Boehringer Ingelheim - Recruiting 1 year to 5 years.
- A Phase II/III, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution (2.5 æg and 5 æg) Administered Once Daily in the Afternoon Via Respimatr Inhaler for 12 Weeks in Patients 1 to 5 Years Old With Persistent Asthma.
tiotropium-bromide; placebo

Diabetes Mellitus, Type 2, or Hyperglycemia Clinical Trial using Empagliflozin low dose qd; Metformin 500 mg bid; Metformin 1000 mg bid; Empagliflozin high dose qd; Empagliflozin low dose bid; Empagliflozin high dose bid

Boehringer Ingelheim - Recruiting 18 years or older.
- A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus.
Empagliflozin low dose qd; Metformin 500 mg bid; Metformin 1000 mg bid; Empagliflozin high dose qd; Empagliflozin low dose bid; Empagliflozin high dose bid

Neoplasms Clinical Trial using volasertib; itraconazole

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours.
volasertib; itraconazole

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib; loperamide

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM).
afatinib; loperamide

Diabetes Mellitus, Type 2 Clinical Trial using Trazenta

Boehringer Ingelheim - Recruiting N/A or older.
- Post Marketing Surveillance on Long Term Drug Use of Trazentar Tablets as add-on Therapy in Patients With Type 2 Diabetes Mellitus.
Trazenta

Lymphoma, Follicular Clinical Trial using BI 695500; MabThera

Boehringer Ingelheim - Recruiting 18 years or older.
- A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma.
BI 695500; MabThera

Carcinoma, Non-Small-Cell Lung Clinical Trial using Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
Afatinib

Arthritis, Rheumatoid Clinical Trial using BI 695500

Boehringer Ingelheim - Recruiting 18 years to 82 years.
- Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial.
BI 695500

Leukemia, Myeloid, Acute Clinical Trial using decitabine iv; volasertib iv infusion

Boehringer Ingelheim - Recruiting 60 years or older.
- An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia.
decitabine iv; volasertib iv infusion

Healthy Clinical Trial using itraconazole; BI 691751

Boehringer Ingelheim - Recruiting 18 years to 50 years.
- Relative Bioavailability of a Single Oral Dose of BI 691751 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study).
itraconazole; BI 691751

Carcinoma, Hepatocellular Clinical Trial using Nintedanib high dose; Nintedanib low dose; Nintedanib medium dose

Boehringer Ingelheim - Recruiting 20 years or older.
- An Open Label, Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Continuous Twice-daily Oral Treatment of Nintedanib in Japanese Patients With Hepatocellular Carcinoma..
Nintedanib high dose; Nintedanib low dose; Nintedanib medium dose

Healthy Clinical Trial using Dabigatran etexilate

Boehringer Ingelheim - Recruiting 18 years to 55 years.
- Relative Bioavailability of Dabigatran After Administration of Different Dosage Forms of Multiple Doses of 150 mg Dabigatran Etexilate (Hard Capsule, Granules Resolved in Reconstitution Solution, Pellets on Food) in Healthy Male Volunteers (an Open-label, Randomised, Multiple-dose, Three Way Crossover Study).
Dabigatran etexilate

Lymphoma, Non-Hodgkin Clinical Trial using BI 836826

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin.
BI 836826

Arthroplasty, Replacement, or Thromboembolism Clinical Trial

Boehringer Ingelheim - Recruiting 18 years or older.
- Observational Cohort Study to Evaluate Safety and Efficacy of Pradaxa (Dabigatran Etexilate) in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery.

Stroke, or Atrial Fibrillation Clinical Trial

Boehringer Ingelheim - Recruiting 18 years or older.
- GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III).

Carcinoma, Non-Small-Cell Lung Clinical Trial using Dose escalation followed by treatment with MTD

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations.
Dose escalation followed by treatment with MTD

Breast Neoplasms, or Stomach Neoplasms Clinical Trial using Herceptin; afatinib; trastuzumab

Boehringer Ingelheim - Recruiting 18 years or older.
- Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. Once the MTD of Afatinib With 3 Weekly Trastuzumab Was Established the Safety of This Dose Will be Assessed Also in Combination With Weekly Trastuzumab..
Herceptin; afatinib; trastuzumab

Neoplasms Clinical Trial using BI 853520

Boehringer Ingelheim - Recruiting 20 years or older.
- An Open-label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Japanese and Taiwanese Patients With Various Advanced or Metastatic Solid Tumours.
BI 853520

Pain, Postoperative, or Tooth Diseases Clinical Trial using Ibuprofen and caffeine; ibuprofen + caffeine; placebo; caffeine; ibuprofen

Boehringer Ingelheim - Recruiting 18 years to 55 years.
- A Single-centre, Double-blind, Randomised, Two-stage, Parallel-group Study to Assess the Efficacy and Safety of the Fixed Dose Combination of Ibuprofen 400 mg and Caffeine 100 mg Versus Ibuprofen 400 mg, Caffeine 100 mg and Placebo in Patients With Postoperative Dental Pain.
Ibuprofen and caffeine; ibuprofen + caffeine; placebo; caffeine; ibuprofen

Common Cold Clinical Trial using Placebo; Iota-Carrageenan

Boehringer Ingelheim - Recruiting 18 years to 64 years.
- Efficacy and Safety of Iota-Carrageenan Nasal Spray 1.2 g/l (0.12 Percent) (Bisolviral) Versus Placebo Nasal Spray in the Early Treatment of Common Cold.
Placebo; Iota-Carrageenan

Pulmonary Disease, Chronic Obstructive Clinical Trial using fluticasone propionate; salmeterol; placebo; tiotropium; olodaterol

Boehringer Ingelheim - Recruiting 40 years or older.
- Randomized, Double-blind, Double-dummy, Active-controlled, 4 Period Complete Cross-over Study to Compare the Effect on Lung Function of 6 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimatr Inhaler vs. 6 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Accuhalerr in Patients With Chronic Obstructive Pulmonary Disease (COPD).
fluticasone propionate; salmeterol; placebo; tiotropium; olodaterol

Purpura, Thrombocytopenic, Idiopathic Clinical Trial using BI 655064

Boehringer Ingelheim - Recruiting 18 years or older.
- Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura..
BI 655064

Venous Thromboembolism Clinical Trial using dabigatran etexilate

Boehringer Ingelheim - Recruiting 1 year to 11 years.
- Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Successive Groups of Children Aged 2 Years to Less Than 12 Years Followed by 1 Year to Less Than 2 Years.
dabigatran etexilate

Leukemia, Lymphocytic, Chronic, B-Cell Clinical Trial using BI 836826

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia.
BI 836826

Diabetes Mellitus, Type 2 Clinical Trial using placebo; BI1356 low dose; BI1356 high dose

Boehringer Ingelheim - Recruiting 10 years to 17 years.
- A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus.
placebo; BI1356 low dose; BI1356 high dose

Neoplasms Clinical Trial using BI 836845

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Patients With Advanced Solid Cancers With Repeated Administrations in Patients Showing Clinical Benefit.
BI 836845

Leukemia, Myeloid, Acute Clinical Trial using BI 836858

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia..
BI 836858

Stroke, or Atrial Fibrillation Clinical Trial

Boehringer Ingelheim - Recruiting 18 years or older.
- GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States).

Atrial Fibrillation Clinical Trial

Boehringer Ingelheim - Recruiting 18 years or older.
- The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis.

Atrial Fibrillation Clinical Trial using Pradaxa, dabigatran etexilate

Boehringer Ingelheim - Recruiting 18 years or older.
- A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy.
Pradaxa, dabigatran etexilate

Asthma Clinical Trial using Placebo; Tiotropium low dose mcg; Tiotropium high dose

Boehringer Ingelheim - Recruiting 6 years to 11 years.
- A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Children (6 to 11 Years Old) With Severe Persistent Asthma.
Placebo; Tiotropium low dose mcg; Tiotropium high dose

Psoriasis Clinical Trial using BI 655066; Ustekinumab

Boehringer Ingelheim - Recruiting 18 years to 75 years.
- A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066).
BI 655066; Ustekinumab

Venous Thromboembolism Clinical Trial using dabigatran etexilate

Boehringer Ingelheim - Recruiting 1 year to 2 years.
- Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89.
dabigatran etexilate